Managing low sexual desire in women

Women's Health

Volumn 7, Issue 5, 2011, Pages 571-583

  Maclaran, Kate ^a,b   Panay, Nick ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

female sexual dysfunction; hypoactive sexual desire disorder; low libido; testosterone

Indexed keywords

ALBUMIN; AMFEBUTAMONE; ANDROGEN; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; FLIBANSERIN; NORADRENALIN; NORETHISTERONE ACETATE; OIL; OXYTOCIN; PLACEBO; PRASTERONE; PROLACTIN; SEROTONIN UPTAKE INHIBITOR; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; SILICONE; TESTOSTERONE; TIBOLONE; WATER;

AGING; APPLICATION SITE IRRITATION; AROUSAL; COMBINATION CHEMOTHERAPY; DIZZINESS; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG RELEASE; ESTROGEN THERAPY; FATIGUE; FEMALE SEXUAL DYSFUNCTION; GENERAL PRACTICE; GYNECOLOGY; HIRSUTISM; HUMAN; HUMAN RELATION; HYPOACTIVE SEXUAL DESIRE DISORDER; INSOMNIA; LIBIDO; MENOPAUSE; MONOTHERAPY; NAUSEA; PATHOGENESIS; PHYSIOLOGICAL PROCESS; PREMATURE OVARIAN FAILURE; PREVALENCE; PSYCHIATRY; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; REVIEW; SEXUAL FUNCTION; SEXUAL HEALTH; SINGLE DRUG DOSE; SOCIAL ASPECT; SYSTEMATIC REVIEW; TRANSDERMAL PATCH; TREATMENT DURATION; VAGINA ATROPHY; VAGINAL DRYNESS;

BUPROPION; DOPAMINE UPTAKE INHIBITORS; EDUCATION, MEDICAL, CONTINUING; FEMALE; HUMANS; LIBIDO; MENOPAUSE; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; WOMEN'S HEALTH;

EID: 80052491398     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.11.54     Document Type: Review

References (75)

1. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women. Prevalence and correlates. Obstet. Gynecol. 112(5), 970-978 (2008).
2. Masters WH, Johnson VE. Human Sexual Response. Little, Brown and company, Boston, MA, USA (1966).
3. Kaplan HS. Hypoactive sexual desire. J. Sex Marital Ther. 3(1), 3-9 (1977). (Pubitemid 8115631)
4. Basson R. Using a different model for female sexual response to address women's problematic low sexual desire. J. Sex Marital Ther. 27(5), 395-403 (2001). (Pubitemid 32802773)
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition, text revision (DSM-IV-TR).American Psychiatric Association, Washington DC, USA (2000).
6. World Health Organization. International Statistical Classification of Diseases and Related Health Problems. 10th revision. World Health Organization, Geneva, Switzerland (1992).
7. Basson R, Leiblum S, Brotto L et al. Definitions of women's sexual dysfunctions reconsidered: advocating expansion and revision. J. Psychosom. Obstet. Gynaecol. 24(4), 221-229 (2003). (Pubitemid 38010480)
8. Basson R, Wierman M, van Lankveld J, Brotto LA. Summary of the recommendations of sexual dysfunction in women. J. Sex. Med. 7(1 Pt 2), 314-326 (2010).
9. Brotto LA, Bitzer J, Laan E, Leiblum S, Luria M. Women's sexual desire and arousal disorders. J. Sex. Med. 7(1 Pt 2), 586-614 (2010).
10. Brotto LA. The DSM diagnostic criteria for hypoactive sexual desire disorder in women. Arch. Sex Behav. 39(2), 221-239 (2010).
11. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States. prevalence and predictors. JAMA 281(6), 537-544 (1999). (Pubitemid 29081307)
12. Moynihan R. Merging of marketing and medical science. BMJ 341, 698-700 (2010).
13. Leiblum SR, Koochaki PE, Rodenberg CA, Barton IP, Rosen RC. Hypoactive sexual desire disorder in postmenopausal women. US results from the Women's International Study of Health and Sexuality (WISHeS).Menopause 13(1), 46-56 (2006).
14. Dennerstein L, Koochaki P, Barton I, Graziottin A. Hypoactive sexual desire disorder in menopausal women: a survey of Western European women. J. Sex. Med. 3(2), 212-222 (2006).
15. Hayes RD, Dennerstein L, Bennett CM, Koochaki PE, Leiblum SR, Graziottin A. Relationship between hypoactive sexual desire disorder and aging. Fertil. Steril. 87(1), 107-112 (2007). (Pubitemid 46019817)
16. West SL, D'Aloisio AA, Agans RP, Kalsbeek WD, Borisov NN, Thorp JM. Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women. Arch. Intern. Med. 168(13), 1441-1449 (2008). (Pubitemid 352008425)
17. Biddle AK, West SL, D'Aloisio AA, Wheeler SB, Borisov NN, Thorp J. Hypoactive sexual desire disorder in postmenopausal women: quality of life and health burden. Value Health. 12(5), 763-772 (2009).
18. Pfaus JG. Pathways of sexual desire. J. Sex. Med. 6(6), 1506-1533 (2009).
19. NEW REF 1 Hull EM, Lorrain DS, Du J et al. Hormone-neurotransmitter interactions in the control of sexual behavior. Behav. Brain Res. 105(1), 105-116 (1999).
20. Genazzani AR, Schneider HP, Panay N, Nijland EA. The European Menopause Survey 2005 Women's perceptions on the menopause and postmenopausal hormone therapy. Gynecol. Endocrinol. 22(7), 369-375 (2006). (Pubitemid 44180263)
21. Levine KB, Williams RE, Hartmann KE. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 15(4 Pt 1), 661-666 (2008).
22. Basson R. Women's sexual function and dysfunction: current uncertainties, future directions. Int. J. Impot. Res. 20(5), 466-478 (2008).
23. Shifren JL. The role of androgens in female sexual dysfunction. Mayo Clin. Proc. 79(Suppl. 4), S19-S24 (2004). (Pubitemid 38401761)
24. Zumoff B, Strain GW, Miller LK, Rosner W. Twenty-four-hour mean plasma testosterone concentration declines with age in normal premenopausal women. J. Clin. Endocrinol. Metab. 80(4), 1429-1430 (1995).
25. Demers LM. Androgen deficiency in women; role of accurate testosterone measurements. Maturitas 67(1), 39-45 (2010).
26. Labrie F, Luu-The V, Labrie C et al. Endocrine and intracrine sources of androgens in women. inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr. Rev. 24(2), 152-182 (2003). (Pubitemid 36515283)
27. Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, von Mühlen D. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study. J. Clin. Endocrinol. Metab. 85(2), 645-651 (2000). (Pubitemid 32273648)
28. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J. Clin. Endocrinol. Metab. 90(7), 3847-3853 (2005). (Pubitemid 41058142)
29. van der Stege JG, Groen H, van Zadelhoff SJ et al. Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. Menopause 15(1), 23-31 (2008).
30. Kalantaridou SN, Calis KA, Vanderhoof VH et al. Testosterone deficiency in young women with 46,XX spontaneous premature ovarian failure. Fertil. Steril. 86(5), 1475-1482 (2006). (Pubitemid 44602054)
31. Kalantaridou SN, Vanderhoof VH, Calis KA, Corrigan EC, Troendle JF, Nelson LM. Sexual function in young women with spontaneous 46,XX primary ovarian insufficiency. Fertil. Steril. 90(5), 1805-1811 (2008).
32. de Almeida DM, Benetti-Pinto CL, Makuch MY. Sexual function of women with premature ovarian failure. Menopause 18(3), 262-266 (2011).
33. Dennerstein L, Hayes R, Sand M, Lehert P. Attitudes toward and frequency of partner interactions among women reporting decreased sexual desire. J. Sex. Med. 6(6),1668-1673 (2009).
34. Harsh V, McGarvey EL, Clayton AH. Physician attitudes regarding hypoactive sexual desire disorder in a primary care clinic: a pilot study. J. Sex. Med. 5(3), 640-645 (2008). (Pubitemid 351337891)
35. Clayton AH, Goldfischer ER, Goldstein I, Derogatis L, Lewis-D'Agostino DJ, Pyke R. Validation of the decreased sexual desire screener (DSDS): a brief diagnostic instrument for generalized acquired female hypoactive sexual desire disorder (HSDD).J. Sex. Med. 6(3), 730-738 (2009).
36. Rosen R, Brown C, Heiman J et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J. Sex Marital Ther. 26(2), 191-208 (2000). (Pubitemid 30194541)
37. McHorney CA, Rust J, Golombok S et al. Profile of female sexual function: a patient-based, international, psychometric instrument for the assessment of hypoactive sexual desire in oophorectomized women. Menopause 11(4), 474-483 (2004). (Pubitemid 40372094)
38. Alzzawi F, Bitzer J, Brandenburg U et al. Therapeutic options for postmenopausal female sexual dysfunction. Climacteric. 13(2), 103-120 (2010).
39. McCabe M, Althof SE, Assalian P et al. Psychological and interpersonal dimensions of sexual function and dysfunction. J. Sex. Med. 7(1 Pt 2), 327-336 (2010).
40. McCabe MP. Evaluation of a cognitive behavior therapy program for people with sexual dysfunction. J. Sex Marital Ther. 27(3), 259-271 (2001). (Pubitemid 32374398)
41. Trudel G, Marchand A, Ravart M, Aubin S, Turgeon L, Fortier P. The effect of a cognitive-behavioral treatment program on hypoactive sexual desire in women. Sex. Relat. Ther. 16(2), 145-164 (2001). (Pubitemid 32529606)
42. Palacios S. Hypoactive sexual desire disorder and current pharmacotherapeutic options in women. Women's Health (Lond. Engl.).7(1), 95-107 (2011).
43. Nappi RE, Polatti F. The use of estrogen therapy in women's sexual functioning (CME).J. Sex. Med. 6(3), 603-616 (2009).
44. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst. Rev. (4), CD001500 (2005).
45. Sturdee DW, Panay N; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 13(6), 509-522 (2010).
46. Flöter A, Nathorst-Böös J, Carlström K, von Schoultz B. Addition of testosterone to estrogen replacement therapy in oophorectomized women: effects on sexuality and well-being. Climacteric 5(4), 357-365 (2002). (Pubitemid 36149723)
47. Lobo RA, Rosen RC, Yang HM, Block B, Van Der Hoop RG. Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. Fertil. Steril. 79(6), 1341-1352 (2003). (Pubitemid 36687880)
48. Shifren JL, Braunstein GD, Simon JA et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N. Engl. J. Med. 343(10), 682-688 (2000).
49. Braunstein GD, Sundwall DA, Katz M et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch. Intern. Med. 165(14), 1582-1589 (2005). (Pubitemid 41124151)
50. Buster JE, Kingsberg SA, Aguirre O et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet. Gynecol. 105(5 Pt 1), 944-952 (2005). (Pubitemid 40571010)
51. Simon J, Braunstein G, Nachtigall L et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J. Clin. Endocrinol. Metab. 90(9), 5226-5233 (2005). (Pubitemid 41262278)
52. Shifren JL, Davis SR, Moreau M et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause 13(5), 770-779 (2006).
53. Panay N, Alzzawi F, Bouchard C et al. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric 13(2), 121-131(2010).
54. Davis SR, Moreau M, Kroll R et al. Testosterone for low libido in postmenopausal women not taking estrogen. N. Engl. J. Med. 359(19), 2005-2017 (2008).
55. Nachtigall L, Casson P, Lucas J, Schofield V, Melson C, Simon JA. Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen. Gynecol. Endocrinol. 27(1), 39-48 (2011).
56. Studd JWW, Collins WP, Chakravarti S, Newton JR, Oram D, Parsons A. Oestradiol and testosterone implants in the treatment of psychosexual problems of postmenopausal women. Br. J. Obstet. Gynecol. 84(4), 314-315 (1977). (Pubitemid 8118602)
57. Burger H, Hailes J, Nelson J, Menelaus M. Effect of combined implants of oestradiol and testosterone on libido in postmenopausal women. Br. Med. J. (Clin. Res. Ed.) 294(6577), 936-937 (1987).
58. Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 21(3), 227-236 (1995).
59. Glaser R, York AE, Dimitrakakis C. Beneficial effects of testosterone therapy in women measured by the validated Menopause Rating Scale (MRS).Maturitas 68(4), 355-361 (2011).
60. Nathorst-Böös J, Flöter A, Jarkander-Rolff M, Carlström K, Schoultz B. Treatment with percutanous testosterone gel in postmenopausal women with decreased libido - effects on sexuality and psychological general well-being. Maturitas 53(1), 11-18 (2006). (Pubitemid 41742067)
61. Chudakov B, Ben Zion IZ, Belmaker RH. Transdermal testosterone gel prn application for hypoactive sexual desire disorder in premenopausal women: a controlled pilot study of the effects on the arizona sexual experiences scale for females and sexual function questionnaire. J. Sex. Med. 4(1), 204-208 (2007). (Pubitemid 46002384)
62. Castelo-Branco C, Vicente JJ, Figueras F et al. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 34(2), 161-168 (2000). (Pubitemid 30068655)
63. Laan E, van Lunsen RH, Everaerd W. The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric 4(1), 28-41 (2001). (Pubitemid 32448485)
64. Nijland EA, Weijmar Schultz WC, Nathorst-Boös J et al. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. J. Sex. Med. 5(3), 646-656 (2008).
65. Cummings SR, Ettinger B, Delmas PD et al. The effects of tibolone in older postmenopausal women. N. Engl. J. Med. 359(7), 697-708 (2008).
66. Labrie F, Bélanger A, Cusan L, Gomez JL, Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. J. Clin. Endocrinol. Metab. 82(8), 2396-2402 (1997). (Pubitemid 27337846)
67. Panjari M, Davis SR. DHEA for postmenopausal women: a review of the evidence. Maturitas 66(2), 172-179 (2010).
68. Labrie F, Archer D, Bouchard C et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 16(5), 923-931 (2009).
69. Stahl SM, Sommer B, Allers KA. Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. J. Sex. Med. 8(1), 15-27 (2011).
70. Jolly E, Clayton AH, Thorp J et al. Efficacy of flibanserin 100 mg qhs as a potential treatment for hypoactive sexual desire disorder in premenopausal women. J. Sex. Med. 6(Suppl. 5), 465 (2009).
71. Segraves RT, Clayton A, Croft H, Wolf A, Warnock J. Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women. J. Clin. Psychopharmacol. 24(3), 339-342 (2004). (Pubitemid 38658043)
72. Safarinejad MR, Hosseini SY, Asgari MA, Dadkhah F, Taghva A. A randomized, double-blind, placebo-controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women. BJU Int. 106(6), 832-839 (2010).
73. Dording CM, Mischoulon D, Petersen TJ et al. The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists. Ann. Clin. Psychiatry 14(3), 143-147 (2002). (Pubitemid 36172562)
74. Safarinejad MR. Reversal of SSRI-induced female sexual dysfunction by adjunctive bupropion in menstruating women: a double-blind, placebo-controlled and randomized study. J. Psychopharmacol. 25(3), 370-378 (2011).
75. Moll JL, Brown CS. The use of monoamine pharmacological agents in the treatment of sexual dysfunction: evidence in the literature. J. Sex. Med. 8(4), 956-970 (2011).